NDC 0409-1810 - Novocaine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-1810
- Package NDCs from labels
- 0409-1810-02
- Manufacturer
- Hospira, Inc.
- Effective date
- 2007-08-28
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NOVOCAIN ® PROCAINE HYDROCHLORIDE INJECTION, USP | Hospira, Inc. | 2007-08-28 | Human prescription drug label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0409-1810-02 | Novocaine | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 2 | |
| 0409-1810-02 | Novocaine | 5 in 1 CONTAINER | INJECTION, SOLUTION | 5 | 2 | |
| 0409-1810-02 | Novocaine | 40 in 1 CASE | INJECTION, SOLUTION | 40 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| Procaine Hydrochloride | ACTIVE INGREDIENT | 95URV01IDQ | NOVOCAINE (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 2 | |
| Procaine | ACTIVE MOIETY | 4Z8Y51M438 | NOVOCAINE (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 2 | |
| Acetone Sodium Bisulfite | INACTIVE INGREDIENT | NOVOCAINE (PROCAINE HYDROCHLORIDE) INJECTION, SOLUTION [HOSPIRA, INC.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Pamidronate Disodium | PAMIDRONATE DISODIUM | Hospira, Inc. | 9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23 | 2026-05-14 | Warnings, Adverse reactions | Hospira, Inc. |
| DOPamine Hydrochloride | DOPAMINE HYDROCHLORIDE | Hospira, Inc. | 1f306ad2-3606-4525-5a8a-ce78f426c1a2 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| Furosemide | FUROSEMIDE | Hospira, Inc. | 39fd32f2-6bb7-4a65-d298-e48d26bc80c7 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| FUROSEMIDE | FUROSEMIDE | Hospira, Inc. | aaced7a8-c3d7-4d66-8c07-aa407b8b3f35 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| ZINC | ZINC CHLORIDE | Hospira, Inc. | 9a1914a0-e195-4233-c1be-bc2075580eb8 | 2026-05-13 | Warnings, Adverse reactions | Hospira, Inc. |
| Dopamine Hydrochloride in Dextrose | DOPAMINE HYDROCHLORIDE IN DEXTROSE | Hospira, Inc. | 08f23f6e-150d-45ea-098e-f2edf64c21a1 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Ketamine Hydrochloride | KETAMINE HYDROCHLORIDE | Hospira, Inc. | bb912318-2e22-4469-b0a2-774803ee1bb8 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Heparin Sodium | HEPARIN SODIUM | Hospira, Inc. | 0413f511-6b34-4c15-e48b-3fad08baacbe | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Heparin Sodium | HEPARIN SODIUM | Hospira, Inc. | 32e34077-aff1-4ec7-f9b0-b8e240768fb8 | 2026-05-12 | Warnings, Adverse reactions | Hospira, Inc. |
| Sodium Phosphates | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE AND SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | Hospira, Inc. | 6f044d16-295e-43ff-72a3-b045c387bc5c | 2026-05-11 | Warnings, Adverse reactions | Hospira, Inc. |
| Daptomycin | DAPTOMYCIN | Hospira, Inc. | 1957b6ce-7382-4a7b-bf02-3595948d09c6 | 2026-05-08 | Warnings, Adverse reactions | Hospira, Inc. |
| Sterile Water | WATER | Hospira, Inc. | 3a6422e1-feee-4095-8883-2b0837039e6e | 2026-05-07 | Warnings, Adverse reactions | Hospira, Inc. |
| Metoprolol Tartrate | METOPROLOL TARTRATE | Hospira, Inc. | f65e93ec-4db6-44fa-bff1-8ae89aa8243f | 2026-05-04 | Warnings, Adverse reactions | Hospira, Inc. |
| TAZICEF | CEFTAZIDIME | Hospira, Inc. | 40d48c5d-650e-461b-a67b-7e65772d1b92 | 2026-05-04 | Warnings, Adverse reactions | Hospira, Inc. |
| Hetastarch in Sodium Chloride | HETASTARCH | Hospira, Inc. | d64f961a-3e1f-4b04-cf83-604474af2775 | 2026-04-30 | Boxed warning, Warnings, Adverse reactions | Hospira, Inc. |
| Aminocaproic Acid | AMINOCAPROIC ACID | Hospira, Inc. | 1c5bc1dd-e9ec-44c1-9281-67ad482315d9 | 2026-04-30 | Warnings, Adverse reactions | Hospira, Inc. |
| Verapamil Hydrochloride | VERAPAMIL HYDROCHLORIDE | Hospira, Inc. | 70057a53-ca29-4848-ab3d-5e691e2a14a3 | 2026-04-29 | Warnings, Adverse reactions | Hospira, Inc. |
| Potassium Acetate | POTASSIUM ACETATE | Hospira, Inc. | c58f8112-d587-493a-91b7-2b48c80bb7bf | 2026-04-27 | Warnings, Adverse reactions | Hospira, Inc. |
| Potassium Acetate | POTASSIUM ACETATE | Hospira, Inc. | e9772b82-1e2b-4c4b-aa47-677491dbf73c | 2026-04-27 | Warnings, Adverse reactions | Hospira, Inc. |
| Gemcitabine | GEMCITABINE | Hospira, Inc. | dc02a23b-3ff9-4441-aa91-8e9e629a7315 | 2026-04-27 | Warnings, Adverse reactions | Hospira, Inc. |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.